02 September 1996
Prolonged viral hepatitis B - assessment of the clinical status and selected immunologic parameters after the immunocorrection with Levamisole
Maciej JabłkowskiMed Sci Monit 1996; 2(5): HY631-635 :: ID: 500085
Abstract
A coordinated antibody and cellular immune response is required for an efficient clearance of HBV infection. Progression to chronic HBV infection occurs, therefore, in patients with an impaired or incompetent cell-mediated immune system. Levamisole is an immunocorrective drug. To evaluate the efficacy of Levamisole in preventing progression from prolonged viral hepatitis B to a chronic process a placebo controlled trial in 54 patients with prolonged viral hepatitis B was performed. This clinical trial was divided into two stages: Stage I lasted - the first six months of the disease. Levamisole, or Placebo, was administered in two cycles: three times a day 50 mg for 3 successive days, during the fifth and sixth week of hospitalization. Stage II was terminated after the next 18 months of observation. Levamisole was administered in 6 successive cycles separated by an 11-day interval, undertaking the treatment from the beginning of Stage II. Patients were evaluated during the therapy for biochemical, virological and immunological response and followed for at least 15 months after therapy to assess long-term efficacy. Altogether out of 33 patients treated with Levamisole at both observation stages, 31 persons recovered (93.9%). Recovery rate in the Placebo/Levamisole group was 66.7% - out of 21 patients 14 recovered. The comparative statistical analysis of the treatment results obtained in Group I (Levamisole/Levamisole) and Group II (Placebo/Levamisole) at both stages has shown statistically significant results. These results were much more beneficial in Group I (p < 0,05) than in Group II, and were dependent on the applied treatment (Q=0,78). These results indicate that Levamisole is a drug preventing the development of chronic hepatitis B in a relationship to its immunocorrective properties.
Keywords: Hepatitis B virus, prolonged viral hepatitis B, chronic hepatitis B, Levamisole, immunocorrection, cellular immunity
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
08 Mar 2024 : Clinical Research
Evaluation of Foot Structure in Preschool Children Based on Body MassMed Sci Monit In Press; DOI: 10.12659/MSM.943765
15 Apr 2024 : Laboratory Research
The Role of Copper-Induced M2 Macrophage Polarization in Protecting Cartilage Matrix in OsteoarthritisMed Sci Monit In Press; DOI: 10.12659/MSM.943738
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952